Pharmacokinetics of a new oral formulation of amoxicillin

European Journal of Drug Metabolism and Pharmacokinetics
M H PrevotB Rouveix

Abstract

The bioavailability of the recently developed 1 g dispersible tablet form of amoxicillin (B) and the 1 g dispersible tablet in suspension form (C) were compared to that of the 1 g standard reference formulation (A). Twelve healthy volunteers were involved in this single-dose, open, randomized, three-way cross-over study. The mean peak serum levels were 14.1 +/- 4.1 micrograms/ml after A, 15.1 +/- 3.1 micrograms/ml after B and 15.1 +/- 5.4 micrograms/ml after C. The area under the drug concentration versus time curves were 47.6 +/- 12.0 micrograms.h/ml after A, 52.8 +/- 10.2 micrograms.h/ml after B and 51.1 +/- 13.8 micrograms.h/ml after C. On the basis of these two pharmacokinetic parameters, the three formulations were found to be bioequivalent. In addition, the predicted serum concentrations during multiple dosing (3 times a day), derived from the corresponding mean concentrations after a single 1 g dose of C showed that 8 hourly administration would yield therapeutic serum concentrations for infections such as uncomplicated community-acquired pneumonia due to susceptible or less susceptible strains in otherwise healthy subjects.

References

Apr 1, 1977·Journal of Pharmaceutical Sciences·P G WellingP O Madsen
Jan 1, 1977·Antimicrobial Agents and Chemotherapy·D A SpykerW M O'Brien
Jan 1, 1976·The Journal of International Medical Research·B M LengJ M Aubertin
Jan 1, 1992·European Journal of Clinical Pharmacology·J SjövallB Angelin
Jan 1, 1992·European Journal of Clinical Pharmacology·G PaintaudJ O Svensson
Apr 1, 1992·Clinical Pharmacokinetics·V W SteinijansJ H Jonkman
Jul 1, 1992·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·P C Appelbaum
May 1, 1991·The Journal of Antimicrobial Chemotherapy·J F WestphalC Carbon
Dec 19, 1987·Lancet·J T Macfarlane
Feb 1, 1988·The Journal of Infectious Diseases·B VogelmanW A Craig
Oct 1, 1988·The Journal of Infectious Diseases·B VogelmanW A Craig
Mar 1, 1988·Antimicrobial Agents and Chemotherapy·G L Drusano
May 1, 1986·The Journal of Pediatrics·B Vogelman, W A Craig
Jan 1, 1985·The Journal of Antimicrobial Chemotherapy·B S Vogelman, W A Craig
Sep 1, 1985·Clinical Pharmacology and Therapeutics·J SjövallD Westerlund
Jul 1, 1972·British Medical Journal·R SutherlandG N Rolinson
Apr 1, 1972·Antimicrobial Agents and Chemotherapy·G P Bodey, J Nance
Jan 1, 1981·Reviews of Infectious Diseases·R W BundtzenW A Craig
Jan 1, 1981·Reviews of Infectious Diseases·H C Neu
Jan 1, 1981·Reviews of Infectious Diseases·C M Kunin
Nov 1, 1981·The Journal of Antimicrobial Chemotherapy·F Nordbring
Aug 1, 1994·The Journal of Antimicrobial Chemotherapy·K P Klugman

❮ Previous
Next ❯

Citations

Jan 8, 2004·Biological & Pharmaceutical Bulletin·Francisco Carlos GroppoThales Rocha Mattos-Filho
Oct 1, 2006·Journal of Applied Oral Science : Revista FOB·Thales Rocha Mattos FilhoFábio Ferreira Perazzo

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.